ScreenerHero

RX BioSyent Inc.

TSXV · CA · Healthcare · Drug Manufacturers - Specialty & Generic · biosyent.com
16.51CAD-1.31%Mkt Cap: 136.85M $P/E: 19.68

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.30BUSDP/E 25.0
TAK
Takeda Pharmaceutical Company Limited
$56.90BUSD
TEVA
Teva Pharmaceutical Industries Limited
$46.26BUSDP/E 66.1
HLN
Haleon plc
$38.79BUSDP/E 18.0
ZTS
Zoetis Inc.
$29.51BUSDP/E 11.7
ZOE
Zoetis Inc.
$28.27BUSDP/E 12.1
UTHR
United Therapeutics Corporation - Common Stock
$23.23BUSDP/E 19.4
VTRS
Viatris Inc. - Common Stock
$20.22BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.14BUSDP/E 110.6
NBIX
Neurocrine Biosciences, Inc. - Common Stock
$14.55BUSDP/E 21.0
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.25BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.26BUSDP/E 28.0
KRK
Krka, d. d.
$8.59BUSDP/E 19.2
AMRX
Amneal Pharmaceuticals, Inc. - Class A Common Stock
$7.07BUSDP/E 42.3
ALKS
Alkermes plc - Ordinary Shares
$7.00BUSDP/E 109.9
HIMS
Hims & Hers Health, Inc.
$6.92BUSD
LNTH
Lantheus Holdings, Inc. - Common Stock
$6.53BUSDP/E 23.9
KNSA
Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares
$5.83BUSDP/E 76.6
INDV
Indivior Pharmaceuticals, Inc. - Common Stock
$4.21BUSDP/E 12.8

Key Statistics

Company
Market Cap136.85M USD
Enterprise Value133.56M USD
Revenue (TTM)40.55M USD
Gross Profit24.01M USD
Net Income (TTM)6.56M USD
Revenue/Share4.92 CAD
Last Price16.51 CAD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)19.68
P/E (Forward)29.88
PEG—
EV/EBITDA12.32
EV/Revenue3.29
P/S3.38
P/B4.14
EPS (TTM)0.85
EPS (Forward)0.56
52W Range
10.6586% of range17.50
52W High17.50 CAD
52W Low10.65 CAD
Profitability
Gross Margin76.57%
Oper. Margin20.60%
EBITDA Margin26.73%
Profit Margin20.93%
ROE21.73%
ROA18.23%
Growth
Revenue Growth95.20%
Earnings Growth39.20%
Cash Flow & Leverage
Operating CF6.56M USD
CapEx (TTM)283.88K USD
FCF Margin13.63%
FCF Yield4.04%
Net Debt-4.23M USD
Net Debt/EBITDA-0.39
Balance Sheet
Debt/Equity0.02
Current Ratio2.07
Quick Ratio1.13
Book Value/Sh4.04 CAD
Cash/Share0.79 CAD
Dividends
Fwd Div Rate0.22 CAD
Trail. Div Rate0.21 CAD
Div. Yield1.32%
5Y Avg Yield—
Payout Ratio24.59%
Ex-Div DateAug 31, 2026
Pay DateSep 15, 2026
Analyst Consensus
Rating—
Target (Mean)18.00 CAD
Upside (mean)+9.0%
Target Range18.00 CAD – 18.00 CAD
# Analysts1
Ownership
Shares Out.11.23M
Float9.14M
Insiders34.95%
Institutions4.13%
Short Interest
Short Ratio0.4d
Short % Out.0.03%
Shares Short3.10K
Short (prev mo.)2.57K
Technical
SMA 5015.61 (+5.8%)
SMA 20014.55 (+13.5%)
Beta0.64
S&P 52W Chg14.58%
Avg Vol (30d)10.35K
Avg Vol (10d)5.39K
Technical Indicators
RSI (14)59.2
MACD0.3615
MACD Signal0.3507
MACD Hist.+0.0109
BB Upper17.16 CAD
BB Middle16.19 CAD
BB Lower15.22 CAD
BB Width11.99%
ATR (14)0.4074 CAD
Vol Ratio (20d)0.38x